Generic drugmakers win a long-running battle with California over a law to ban pay-to-delay deals

Taking stock of the drug industry, from the lab to the medicine chest

February 18, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

APStock STAT+ | Generic drugmakers win a long-running battle with California over a law to ban pay-to-delay deals State officials said the law was necessary to prevent drug companies from thwarting competition and maintaining higher prices. By Ed Silverman STAT+ | Biogen partners with Stoke Therapeutics on drug for severe epilepsy Called zorevunersen, the Stoke drug has shown potential to become the first treatment to target the underlying, genetic cause of the condition. By Adam Feuerstein STAT+ | Duchenne gene therapy from Solid Biosciences produces promising results in early study The company is one of several trying to develop an improved gene therapy for the genetic muscle wasting condition. By Jason Mast Anna Moneymaker/Getty Images STAT+ | Drug inspectors, AI experts, maternal health workers: Trump's health agency cuts are far-reaching 'Read this email immediately.' Stories from people getting HHS layoff notices and their work on pharmaceutical inspections, medical device safety, AI health care. By Helen Branswell

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser